NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Major depressive disorder afflicts ~16 percent of the world population at some point in their lives. Despite a number of available monoaminergic-based antidepressants, most patients require many weeks, if not months, to respond to these treatments, and many patients never attain sustained remission...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanos, Panos, Moaddel, Ruin, Morris, Patrick J., Georgiou, Polymnia, Fischell, Jonathan, Elmer, Greg I., Alkondon, Manickavasagom, Yuan, Peixiong, Pribut, Heather J., Singh, Nagendra S., Dossou, Katina S.S., Fang, Yuhong, Huang, Xi-Ping, Mayo, Cheryl L., Wainer, Irving W., Albuquerque, Edson X., Thompson, Scott M., Thomas, Craig J., Zarate, Carlos A., Gould, Todd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922311/
https://www.ncbi.nlm.nih.gov/pubmed/27144355
http://dx.doi.org/10.1038/nature17998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922311/
https://www.ncbi.nlm.nih.gov/pubmed/27144355
http://dx.doi.org/10.1038/nature17998

Ejemplares similares